The cost of Trelegy (fluticasone furoate, umeclidinium, and vilanterol) can vary depending on factors such as insurance coverage, pharmacy, and whether a generic version is available.
What is the typical price range for Trelegy?
Without insurance, a 30-day supply of Trelegy Ellipta inhaler can range from approximately $450 to $550 [1]. The exact cost can fluctuate based on the specific pharmacy and location.
How can I get financial assistance for Trelegy?
For commercially insured patients, manufacturer-sponsored savings cards may help reduce out-of-pocket costs, potentially bringing them down to as little as $10 per prescription [1]. Details on eligibility and how to obtain these savings cards are typically available through the drug manufacturer's website or by inquiring at your pharmacy.
Are there any patient assistance programs for Trelegy?
Patient assistance programs may be available for eligible uninsured or underinsured individuals. These programs aim to make the medication more affordable for those who meet specific income and coverage criteria [1]. Information on these programs can often be found by contacting the pharmaceutical company that produces Trelegy or through independent patient advocacy groups.
When does the patent for Trelegy expire?
The patent expiry dates for Trelegy are complex due to multiple patents covering the drug and its delivery device. According to DrugPatentWatch.com, some key patents for Trelegy are expected to expire around 2027 [2]. However, other patents and potential exclusivities could extend beyond this date, influencing the timeline for generic or biosimilar entry [2].
What are the main components of Trelegy?
Trelegy is a combination inhaler containing three active ingredients: fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, a long-acting muscarinic antagonist (LAMA); and vilanterol, a long-acting beta2-adrenergic agonist ( [3]